Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px
Document › Details

Medivir AB. (12/10/17). "Press Release: Medivir Announces Janssen Decision to Terminate Its Simeprevir License effective June 2018". Stockholm.

Organisations Organisation Medivir AB (Nasdaq Stockholm: MVIR)
  Today Medivir (Group)
  Group Medivir (Group)
  Organisation 2 Janssen Pharmaceuticals Inc.
  Group Johnson & Johnson (JnJ) (Group)
Products Product Olysio™
  Product 2 simeprevir
Index term Index term JnJ–Medivir: antiviral, –201806 license for simeprevir to Janssen Pharmaceuticals Inc TERMINATED 6/18
Person Person Lind, Christine (Medivir 201704– CEO before EVP Strategic BusDev before LifeCellCorp + Merrill Lynch/BoAML in NY)
     


Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen’s assessment of market demand. The termination of the license will become effective in June 2018 and Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time. Medivir will seek to identify potential commercialization partners for specific territories where it believes there may be a market opportunity.

Medivir’s royalty on the global sales of simeprevir in the first three quarters of 2017 were SEK 13.7M, SEK 7.7M, and SEK 4.1M respectively.


For further information, please contact:

Christine Lind, CEO Medivir AB, phone: +46 (0)8 407 4641
Anders Lundin, CFO Medivir AB, phone: +46 (0)73 125 1453


This is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11.30 CET on 10 December 2017.


About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

   
Record changed: 2017-12-15

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px

More documents for Medivir (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px